Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice.
BACKGROUND
Thiazolidinediones (TZDs), which have actions that involve both peroxisome proliferator-activated receptor (PPAR)-gamma-dependent and -independent effects, improve insulin sensitivity in type II diabetes and inhibit early atherogenesis in mice. However, the effects of TZDs on advanced lesion progression are unknown.


RESULTS
Pioglitazone and rosiglitazone enhanced macrophage apoptosis by a number of stimuli, including those thought to be important in advanced atherosclerosis. Macrophage death was not enhanced by non-TZD PPARgamma activators, and TZD-induced apoptosis was still observed in PPARgamma-deficient macrophages. In wild-type macrophages, death enhancement was associated with reduced activation of the cell-survival mediator nuclear factor-kappaB. TZDs also increased the ability of macrophages to phagocytically clear apoptotic cells, which is proposed to protect against plaque necrosis in advanced lesions. The mechanism of this effect was complex, involving both PPARgamma-dependent and -independent mechanisms. To explore the net effect on advanced atherosclerosis in vivo, Ldlr-/- mice were fed a nondiabetogenic cholesterol-enriched diet to promote midstage lesions. Then, pioglitazone was administered with the diet for an additional 10 weeks. Aortic root lesions from the pioglitazone-treated mice showed a substantial increase in apoptotic cells and plaque necrosis compared with lesions from non-drug-treated mice.


CONCLUSIONS
The potential atheroprotective effects of TZDs conferred by insulin sensitization may be partially offset by adverse effects on advanced atherosclerosis. Because the mechanisms of the beneficial and proposed adverse effects may differ, these findings have potentially important implications for drug optimization.
Thorp
Edward
E
Department of Medicine, Columbia University, 630 W 168th St, New York, NY 10032, USA.
Kuriakose
George
G
Shah
Yatrik M
YM
Gonzalez
Frank J
FJ
Tabas
Ira
I
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology; D050197:Atherosclerosis / Q000235:genetics / Q000276:immunology* / Q000473:pathology*; D002470:Cell Survival / Q000187:drug effects / Q000276:immunology; D002784:Cholesterol / Q000378:metabolism / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2; D005260:Female; D007004:Hypoglycemic Agents / Q000633:toxicity*; D008264:Macrophages / Q000166:cytology / Q000473:pathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D009336:Necrosis; D047495:PPAR gamma / Q000235:genetics / Q000378:metabolism; D000077205:Pioglitazone; D011973:Receptors, LDL / Q000235:genetics*; D045162:Thiazolidinediones / Q000633:toxicity*; D051996:Transcription Factor RelA / Q000378:metabolism
D007004:Hypoglycemic Agents; D047495:PPAR gamma; D011973:Receptors, LDL; C498144:Rela protein, mouse; D045162:Thiazolidinediones; D051996:Transcription Factor RelA; D002784:Cholesterol; D000077205:Pioglitazone